Therapeutic drug monitoring of mycophenolate mofetil in transplantation

Teun Van Gelder, Yann Le Meur, Leslie M. Shaw, Michael Oellerich, David DeNofrio, Curtis Holt, David W. Holt, Bruce Kaplan, Dirk Kuypers, Bruno Meiser, Burkhard Toenshoff, Richard D. Mamelok

Research output: Contribution to journalArticle

255 Citations (Scopus)

Abstract

A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide immunosuppression with mycophenolate mofetil was held in New York in December 2004. Existing recommendations for the initial months after transplantation were updated. After ensuring adequate levels of mycophenolic acid (MPA, the active metabolite of mycophenolate mofetil) immediately after transplantation, optimal efficacy may require only a few dose adjustments, because intrapatient variability in exposure seems low. Recommendations based on current knowledge were made for posttransplantation sampling time points and for target MPA concentrations. Algorithms for estimating MPA exposure using limited sampling strategies were presented, and a new assay for MPA discussed. It was agreed that because of interpatient variability and the influence of concomitant immunosuppressants, TDM might help optimize outcomes, especially in patients at higher risk of rejection. The value of TDM in the general transplant population will be assessed from large, ongoing, randomized studies.

Original languageEnglish (US)
Pages (from-to)145-154
Number of pages10
JournalTherapeutic Drug Monitoring
Volume28
Issue number2
DOIs
StatePublished - Apr 2006
Externally publishedYes

Fingerprint

Mycophenolic Acid
Drug Monitoring
Transplantation
Monitoring
Pharmaceutical Preparations
Sampling
Transplants
Immunosuppressive Agents
Metabolites
Immunosuppression
Assays
Population

Keywords

  • Mycophenolate mofetil
  • Therapeutic drug monitoring
  • Transplantation

ASJC Scopus subject areas

  • Toxicology
  • Health, Toxicology and Mutagenesis
  • Pharmacology
  • Biochemistry
  • Biochemistry, Genetics and Molecular Biology(all)
  • Pharmacology (medical)
  • Public Health, Environmental and Occupational Health

Cite this

Van Gelder, T., Meur, Y. L., Shaw, L. M., Oellerich, M., DeNofrio, D., Holt, C., ... Mamelok, R. D. (2006). Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Therapeutic Drug Monitoring, 28(2), 145-154. https://doi.org/10.1097/01.ftd.0000199358.80013.bd

Therapeutic drug monitoring of mycophenolate mofetil in transplantation. / Van Gelder, Teun; Meur, Yann Le; Shaw, Leslie M.; Oellerich, Michael; DeNofrio, David; Holt, Curtis; Holt, David W.; Kaplan, Bruce; Kuypers, Dirk; Meiser, Bruno; Toenshoff, Burkhard; Mamelok, Richard D.

In: Therapeutic Drug Monitoring, Vol. 28, No. 2, 04.2006, p. 145-154.

Research output: Contribution to journalArticle

Van Gelder, T, Meur, YL, Shaw, LM, Oellerich, M, DeNofrio, D, Holt, C, Holt, DW, Kaplan, B, Kuypers, D, Meiser, B, Toenshoff, B & Mamelok, RD 2006, 'Therapeutic drug monitoring of mycophenolate mofetil in transplantation', Therapeutic Drug Monitoring, vol. 28, no. 2, pp. 145-154. https://doi.org/10.1097/01.ftd.0000199358.80013.bd
Van Gelder T, Meur YL, Shaw LM, Oellerich M, DeNofrio D, Holt C et al. Therapeutic drug monitoring of mycophenolate mofetil in transplantation. Therapeutic Drug Monitoring. 2006 Apr;28(2):145-154. https://doi.org/10.1097/01.ftd.0000199358.80013.bd
Van Gelder, Teun ; Meur, Yann Le ; Shaw, Leslie M. ; Oellerich, Michael ; DeNofrio, David ; Holt, Curtis ; Holt, David W. ; Kaplan, Bruce ; Kuypers, Dirk ; Meiser, Bruno ; Toenshoff, Burkhard ; Mamelok, Richard D. / Therapeutic drug monitoring of mycophenolate mofetil in transplantation. In: Therapeutic Drug Monitoring. 2006 ; Vol. 28, No. 2. pp. 145-154.
@article{baa88eeccb2842539fd19c606abdb636,
title = "Therapeutic drug monitoring of mycophenolate mofetil in transplantation",
abstract = "A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide immunosuppression with mycophenolate mofetil was held in New York in December 2004. Existing recommendations for the initial months after transplantation were updated. After ensuring adequate levels of mycophenolic acid (MPA, the active metabolite of mycophenolate mofetil) immediately after transplantation, optimal efficacy may require only a few dose adjustments, because intrapatient variability in exposure seems low. Recommendations based on current knowledge were made for posttransplantation sampling time points and for target MPA concentrations. Algorithms for estimating MPA exposure using limited sampling strategies were presented, and a new assay for MPA discussed. It was agreed that because of interpatient variability and the influence of concomitant immunosuppressants, TDM might help optimize outcomes, especially in patients at higher risk of rejection. The value of TDM in the general transplant population will be assessed from large, ongoing, randomized studies.",
keywords = "Mycophenolate mofetil, Therapeutic drug monitoring, Transplantation",
author = "{Van Gelder}, Teun and Meur, {Yann Le} and Shaw, {Leslie M.} and Michael Oellerich and David DeNofrio and Curtis Holt and Holt, {David W.} and Bruce Kaplan and Dirk Kuypers and Bruno Meiser and Burkhard Toenshoff and Mamelok, {Richard D.}",
year = "2006",
month = "4",
doi = "10.1097/01.ftd.0000199358.80013.bd",
language = "English (US)",
volume = "28",
pages = "145--154",
journal = "Therapeutic Drug Monitoring",
issn = "0163-4356",
publisher = "Lippincott Williams and Wilkins",
number = "2",

}

TY - JOUR

T1 - Therapeutic drug monitoring of mycophenolate mofetil in transplantation

AU - Van Gelder, Teun

AU - Meur, Yann Le

AU - Shaw, Leslie M.

AU - Oellerich, Michael

AU - DeNofrio, David

AU - Holt, Curtis

AU - Holt, David W.

AU - Kaplan, Bruce

AU - Kuypers, Dirk

AU - Meiser, Bruno

AU - Toenshoff, Burkhard

AU - Mamelok, Richard D.

PY - 2006/4

Y1 - 2006/4

N2 - A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide immunosuppression with mycophenolate mofetil was held in New York in December 2004. Existing recommendations for the initial months after transplantation were updated. After ensuring adequate levels of mycophenolic acid (MPA, the active metabolite of mycophenolate mofetil) immediately after transplantation, optimal efficacy may require only a few dose adjustments, because intrapatient variability in exposure seems low. Recommendations based on current knowledge were made for posttransplantation sampling time points and for target MPA concentrations. Algorithms for estimating MPA exposure using limited sampling strategies were presented, and a new assay for MPA discussed. It was agreed that because of interpatient variability and the influence of concomitant immunosuppressants, TDM might help optimize outcomes, especially in patients at higher risk of rejection. The value of TDM in the general transplant population will be assessed from large, ongoing, randomized studies.

AB - A roundtable meeting to discuss the use of therapeutic drug monitoring (TDM) to guide immunosuppression with mycophenolate mofetil was held in New York in December 2004. Existing recommendations for the initial months after transplantation were updated. After ensuring adequate levels of mycophenolic acid (MPA, the active metabolite of mycophenolate mofetil) immediately after transplantation, optimal efficacy may require only a few dose adjustments, because intrapatient variability in exposure seems low. Recommendations based on current knowledge were made for posttransplantation sampling time points and for target MPA concentrations. Algorithms for estimating MPA exposure using limited sampling strategies were presented, and a new assay for MPA discussed. It was agreed that because of interpatient variability and the influence of concomitant immunosuppressants, TDM might help optimize outcomes, especially in patients at higher risk of rejection. The value of TDM in the general transplant population will be assessed from large, ongoing, randomized studies.

KW - Mycophenolate mofetil

KW - Therapeutic drug monitoring

KW - Transplantation

UR - http://www.scopus.com/inward/record.url?scp=33745957413&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33745957413&partnerID=8YFLogxK

U2 - 10.1097/01.ftd.0000199358.80013.bd

DO - 10.1097/01.ftd.0000199358.80013.bd

M3 - Article

C2 - 16628123

AN - SCOPUS:33745957413

VL - 28

SP - 145

EP - 154

JO - Therapeutic Drug Monitoring

JF - Therapeutic Drug Monitoring

SN - 0163-4356

IS - 2

ER -